ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

ClinicalTrials.gov ID: NCT00479856

Public ClinicalTrials.gov record NCT00479856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.

Study identification

NCT ID
NCT00479856
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
9 participants

Conditions and interventions

Interventions

  • Capecitabine Drug
  • Docetaxel Drug
  • Lapatinib Drug
  • nab-Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Aug 31, 2009
Completion
Feb 28, 2010
Last update posted
Jun 4, 2012

2007 – 2010

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
GSK Investigational Site Hot Springs Arkansas 71913
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Burbank California 91505
GSK Investigational Site Highland California 92346
GSK Investigational Site Long Beach California 90806
GSK Investigational Site Sacramento California 95819
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Fort Lauderdale Florida 33328
GSK Investigational Site Hollywood Florida 33021
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Atlanta Georgia 30341
GSK Investigational Site Lawrenceville Georgia 30045
GSK Investigational Site Zion Illinois 60099
GSK Investigational Site Indianapolis Indiana 46227
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site New Orleans Louisiana 70112
GSK Investigational Site Baltimore Maryland 21237
GSK Investigational Site Minneapolis Minnesota 55426
GSK Investigational Site Tupelo Mississippi 38801
GSK Investigational Site Voorhees Township New Jersey 08043
GSK Investigational Site Albuquerque New Mexico 87131-0001
GSK Investigational Site New York New York 10016
GSK Investigational Site Sumter South Carolina 29150
GSK Investigational Site Austin Texas 78705
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Ogden Utah 84403
GSK Investigational Site Abingdon Virginia 24211
GSK Investigational Site Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00479856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 4, 2012 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00479856 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →